Recursion Pharmaceuticals Stock Investor Sentiment

RXRX Stock  USD 6.38  0.49  8.32%   
Slightly above 58% of all Recursion Pharmaceuticals' investors are looking to take a long position. The analysis of the overall investor sentiment regarding Recursion Pharmaceuticals suggests that some traders are interested. Recursion Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Recursion Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.

Panic Vs Confidence

58

 
Panic
 
Confidence
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Recursion Pharmaceuticals' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Recursion Pharmaceuticals.

Recursion Historical Sentiment

Although Recursion Pharmaceuticals' investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding Recursion, such as negative comments on social media and news outlets, may cause fear in the market and push Recursion Pharmaceuticals' investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of Recursion.
  

Recursion Pharmaceuticals Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Recursion Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Recursion Pharmaceuticals Historical Investor Sentiment

Investor biases related to Recursion Pharmaceuticals' public news can be used to forecast risks associated with an investment in Recursion. The trend in average sentiment can be used to explain how an investor holding Recursion can time the market purely based on public headlines and social activities around Recursion Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Recursion Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Recursion Pharmaceuticals and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Recursion Pharmaceuticals news discussions. The higher the estimate score, the more favorable the investor's outlook on Recursion Pharmaceuticals.
over three months ago at www.macroaxis.com         
Disposition of 11962 shares by Michael Secora of Recursion Pharmaceuticals at 6.69 subject to Rule 1...
Macroaxis News
over three months ago at www.macroaxis.com         
Disposition of 375 shares by Michael Secora of Recursion Pharmaceuticals at 2.22 subject to Rule 16b...
Macroaxis News
over three months ago at fool.com         
Prediction Artificial Intelligence Will Lead to Higher Returns With Biotech Stocks
fool News
over three months ago at finance.yahoo.com         
Disposition of 375 shares by Michael Secora of Recursion Pharmaceuticals at 2.22 subject to Rule 16b...
Yahoo News
over three months ago at simplywall.st         
Earnings Beat Recursion Pharmaceuticals, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Li...
Simply Wall St News at Macroaxis
over three months ago at fool.com         
Prediction Buying Biotech and Pharma Stocks During This Sell-Off Will Be a Smart Move
fool News
over three months ago at benzinga.com         
Kuehn Law Encourages ITI, RXRX, GVP, and OBDE Investors to Contact Law Firm
benzinga news
over three months ago at fool.com         
Is Recursion Pharmaceuticals a Buy Ahead of Its Merger With Exscientia?
fool News
over three months ago at insidermonkey.com         
Recursion Pharmaceuticals, Inc. Q2 2024 Earnings Call Transcript
insidermonkey News
over three months ago at finance.yahoo.com         
Recursion updates L call on August 8th to 830 am ET 630 am MT
Yahoo News
over three months ago at seekingalpha.com         
Recursion Pharmaceuticals GAAP EPS of -0.40 misses by 0.02, revenue of 14.42M beats by 1.13M
seekingalpha News
over three months ago at gurufocus.com         
Recursion Pharmaceuticals Inc Q2 2024 Earnings Revenue Meets Estimates at 13. ...
Gurufocus Stories at Macroaxis
over three months ago at businesswire.com         
RXRX Stock Alert Halper Sadeh LLC Is Investigating Whether the Merger of Recursion Pharmaceuticals, ...
businesswire News
over three months ago at businesswire.com         
RXRX Stock Alert Halper Sadeh LLC Is Investigating Whether the Merger of Recursion Pharmaceuticals, ...
businesswire News
over three months ago at globenewswire.com         
CORRECTION - Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results
Macroaxis News: globenewswire.com
Far too much social signal, news, headlines, and media speculation about Recursion Pharmaceuticals that are available to investors today. That information is available publicly through Recursion media outlets and privately through word of mouth or via Recursion internal channels. However, regardless of the origin, that massive amount of Recursion data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Recursion Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Recursion Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Recursion Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Recursion Pharmaceuticals alpha.

Recursion Pharmaceuticals Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Disposition of 20000 shares by Christopher Gibson of Recursion Pharmaceuticals at 6.04 subject to Rule 16b-3
09/04/2024
2
Disposition of 20000 shares by Christopher Gibson of Recursion Pharmaceuticals at 6.14 subject to Rule 16b-3
09/05/2024
3
Disposition of 375 shares by Michael Secora of Recursion Pharmaceuticals at 2.22 subject to Rule 16b-3
09/10/2024
4
Recursion Pharmaceuticals, Inc. A Very Important AI Stock According to BlackRock
09/12/2024
5
Disposition of 11447 shares by Blake Borgeson of Recursion Pharmaceuticals at 6.8431 subject to Rule 16b-3
09/17/2024
6
Disposition of tradable shares by Marriott Tina of Recursion Pharmaceuticals at 1.06 subject to Rule 16b-3
09/26/2024
7
Disposition of 50000 shares by Christopher Gibson of Recursion Pharmaceuticals subject to Rule 16b-3
10/21/2024
8
Recursion Pharmaceuticals A Promising Small-Cap in Biotech Innovation
10/23/2024
9
Disposition of 11447 shares by Blake Borgeson of Recursion Pharmaceuticals at 6.7202 subject to Rule 16b-3
10/29/2024
10
Recursion Pharmaceuticals Inc Q3 2024 Earnings Report Preview What To Expect
11/05/2024
11
Recursion Pharmaceuticals Q3 Earnings Snapshot
11/06/2024
12
Recursion Pharmaceuticals, Inc.s Share Price Could Signal Some Risk
11/08/2024
13
Recursion Pharmaceuticals Announces First Amendment to Transaction Agreement with ExscientiaSalt Lake City, UT Recursion Pharmaceuticals, Inc. , a Delaware corp...
11/12/2024
14
FMR LLCs Strategic Acquisition in Recursion Pharmaceuticals Inc
11/13/2024
15
Disposition of 20000 shares by Christopher Gibson of Recursion Pharmaceuticals at 7.35 subject to Rule 16b-3
11/14/2024
16
Recursion Pharmaceuticals director Blake Borgeson sells 87,457 in stock
11/15/2024
17
Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery
11/20/2024
18
Cramers Lightning Round Reddit is fabulous
11/26/2024

Additional Tools for Recursion Stock Analysis

When running Recursion Pharmaceuticals' price analysis, check to measure Recursion Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Recursion Pharmaceuticals is operating at the current time. Most of Recursion Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Recursion Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Recursion Pharmaceuticals' price. Additionally, you may evaluate how the addition of Recursion Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.